General Toxicity Notes
Natriuretic drugs may cause extracellular fluid volume depletion.
Excreted Unchanged %
40-60
Half-Life (Normalesrd) Hours
1.4/1.6-3.4
Plasma Protein Binding %
94
Volume Of Distribution L/Kg
0.3
Dose For Normal Renal Function
6-12 mg q24h
Adjustment For Renal Failure Method
D
Adjustment For Renal Failure Gfr, Ml/Min >50 [Recommended Level]
100% [A]
Adjustment For Renal Failure Gfr, Ml/Min 10-50 [Recommended Level]
100% [A]
Adjustment For Renal Failure Gfr, Ml/Min <10 [Recommended Level]
100% [A]
Supplement For Dialysis [Recommendation Level]: Ihd
IHD: None
Supplement For Dialysis [Recommendation Level]: Pd
PD: None
Supplement For Dialysis [Recommendation Level]: Crrt
CRRT: Not applicable, [D]
References
Clissold SP, Brogden RN. Piretanide. A preliminary review of its pharmacodynamic and pharmacokinetic properties, and therapeutic efficacy. Drugs. 1985; 29: 489-530. [PMID: 3891305] / Marsh JD, Smith TW. Piretanide: a loop-active diuretic. Pharmacology, therapeutic efficacy and adverse effects. Pharmacotherapy. 1984; 4: 170-80. [PMID: 6384944] / Walter U, Rö ckel A, Lahn W, Heidland A, Heptner W. Pharmacokinetics of the loop diuretic piretanide in renal failure. Eur J Clin Pharmacol. 1985; 29: 337-43. [PMID: 4076330]
Toxicity Notes
High doses effective in ESRD. Ototoxicity.